What Is Driving Salarius Pharmaceuticals, Inc. (SLRX) Stock Up In Pre-Market Session?

0
471
GILD Stock
GILD Stock

Shares of biopharma company Salarius Pharmaceuticals, Inc. (SLRX) have been rising +16.58% to $2.25 (as of 09:07 a.m. EST) before the start of the regular session today. The stock has lost -10.65% in the last session closing at $1.93, trading in the range of $1.54 and $2.00 with 2.19 Million shares changed hands.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What Happened?


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Salarius Pharmaceuticals Inc. is involved in cancer research and developing treatments for cancer patients using the biopharmaceutical industry’s leading-edge technologies. Salarius is investigating seclidemstat, its lead candidate, as a potential treatment for pediatric cancers, solid tumors, and other cancers with treatment options not sufficiently available. The U.S. FDA has already granted Fast Track Designation and Orphan Drug Designation for Seclidemstat for relapsed/refractory Ewing Sarcoma which is in phase 1/2 of clinical trials.

Read More

Salarius today announced the start of the expansion phase of the seclidemstat’s ongoing Phase 1/2 clinical trial in patients with relapsing and refractory (R/R) Ewings and Ewing-related sarcomas. The company will be adopting the following strategy in conducting that expanded study:

  • Under the amended trial protocol, two treatment arms will be included in the expansion stage.
  • Seclidemstat will be studied in combination with topotecan inup to 20 Ewing sarcoma patients in the first arm.
  • Seclidemstat will be investigated as a single agent at the RP2D in patients with Ewing-related sarcomas in the second arm.
  • Salarius expects to report readouts from the trial towards the end of 2021 and into 2022. Both the Ewing and Ewing-related sarcoma arms of the trial will evaluate safety and efficacy endpoints.

LEAVE A REPLY

Please enter your comment!
Please enter your name here